AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Intellia Therapeutics, Inc.
Video analysis: NTLA
All videosNo video analysis for this stock yet. Request one from our team.
News: NTLA
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world's first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.
Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA
Public Employees Retirement System of Ohio acquired a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 88,257 shares of the company's stock, valued at approximately $1,493,000. Public Employees Retirement System of Ohio
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.
Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA
Bank of New York Mellon Corp purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 410,654 shares of the company's stock, valued at approximately $6,948,000. Bank of New York Mellon Corp owned approximately
